160 related articles for article (PubMed ID: 37486076)
1. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
2. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
3. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
4. The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms.
Canberk S; Gonçalves J; Rios E; Povoa AA; Tastekin E; Sobrinho-Simões M; Uguz A; Aydin O; Ince U; Soares P; Máximo V
Endocr Pathol; 2024 Mar; 35(1):25-39. PubMed ID: 38285158
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
6. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine.
Hysek M; Paulsson JO; Wang N; Jatta K; Lindh C; Fuentes-Martinez N; Shabo I; Zedenius J; Juhlin CC
Virchows Arch; 2018 Nov; 473(5):639-643. PubMed ID: 29860621
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
9. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
11. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas.
Cracolici V; Ritterhouse LL; Segal JP; Puranik R; Wanjari P; Kadri S; Parilla M; Cipriani NA
Am J Surg Pathol; 2020 Jul; 44(7):881-892. PubMed ID: 32282345
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
13. Comparison of TERT and 5-Hydroxymethylcytocine immunohistochemistry in various thyroid carcinomas.
An HR; Kim WG; Lee YM; Sung TY; Song DE
Ann Diagn Pathol; 2024 Mar; 71():152290. PubMed ID: 38552304
[TBL] [Abstract][Full Text] [Related]
14.
Paulsson JO; Mu N; Shabo I; Wang N; Zedenius J; Larsson C; Juhlin CC
Endocr Relat Cancer; 2018 Jul; 25(7):723-733. PubMed ID: 29692346
[TBL] [Abstract][Full Text] [Related]
15. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.
Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
17. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
[TBL] [Abstract][Full Text] [Related]
19. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
